Learn how Dispatch Biotherapeutics is expanding the curative potential of immunotherapies by dispatching its Flare platform to overcome solid tumors.
Location: United States
Total raised: $216M
Investors 1
| Date | Name | Website |
| 08.11.2023 | ARCH Ventu... | archventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.07.2025 | Series A | $216M | Alexandria... |
Mentions in press and media 7
| Date | Title | Description |
| 06.03.2026 | CARsgen Therapeutics Announces 2025 Annual Results | SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results. Business Highlights Cash and cash e... |
| 12.01.2026 | CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors | SHANGHAI, PHILADELPHIA and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, and Dispatch Bio, a biotech company engine... |
| 19.09.2025 | ARCH-backed Dispatch Bio and Sironax named to Endpoints 11 list of most exciting startups in 2025 | - |
| 25.07.2025 | Dispatch Bio Launched With $216 Million To Develop Solid Tumor Treatments | Dispatch Bio has officially launched with a mission to create a universal treatment for solid tumors, which constitute roughly 90% of cancers. The company has secured a total of $216 million in funding, including a recent Series A round. Th... |
| 24.07.2025 | Dispatch Bio Raises Series A in Funding; Total To $216M | Dispatch Bio, a San Francisco, CA- and Philadelphia, PA-based Biotechnology company developing treatments for tumours, raised an undisclosed amounting Series A funding. Backers included ARCH Venture Partners and PICI, along with Bristol Mye... |
| 23.07.2025 | ARCH-backed Dispatch Bio aims to develop a universal immunotherapy treatment | - |
| - | Dispatch Bio | “Learn how Dispatch Biotherapeutics is expanding the curative potential of immunotherapies by dispatching its Flare platform to overcome solid tumors.” |